Online citations, reference lists, and bibliographies.

Precocious Puberty Therapeutic Management: GnRH Analogs Treatment

C. Bouvattier
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
GnRH analog therapy is an effective treatment for central precocious puberty. The therapeutic management of central precocious puberty should be discussed on clinical criteria (rapidly progressive puberty, advance bone age), biological criteria (LH, inhibin B, estradiol), and ultrasound criteria (uterine length, ovarian volume). The optimal timing of treatment discontinuation has not been clearly evaluated. The average age of discontinuation is around 11 years, the physiological age of puberty in girls. Menarche occurs 12–18 months after the end of treatment. Clinical pubertal signs reappear a few months after the end of the treatment. Compromise of adult height, early menarche, and social and behavioral implications is often a concern for these patients.
This paper references
10.1016/S0022-3476(05)81162-X
Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
E. Neely (1992)
A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty.
K. L. Eckert (1996)
10.1530/EJE-08-0814
The use of GnRH agonists in precocious puberty.
D. Mul (2008)
10.1542/PEDS.110.5.897
Secondary sexual characteristics in children with cerebral palsy and moderate to severe motor impairment: a cross-sectional survey.
G. Worley (2002)
10.1210/JCEM.84.6.5647
Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
J. Carel (1999)
10.1007/S10578-004-3489-2
Precocious Puberty in Adolescent Girls: A Biomarker of Later Psychosocial Adjustment Problems
L. Tremblay (2005)
10.1210/JCEM.84.12.6204
Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
M. Palmert (1999)
10.1159/000063209
Effect of Gonadotropin-Releasing Hormone Agonist Treatment in Boys with Central Precocious Puberty: Final Height Results
D. Mul (2002)
10.1053/BEEM.2002.0188
Treatment of central precocious puberty.
C. Partsch (2002)
10.1210/jc.2010-2745
Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty.
S. S. Mogensen (2011)
10.1530/EJE.0.1410140
Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
T. Arrigo (1999)
10.1159/000308172
Effect of Treatment with Cyproterone Acetate on Uterine Bleeding at the Beginning of GnRH Analogue Therapy in Girls with Idiopathic Central Precocious Puberty
S. Seminara (2010)
10.1093/HUMUPD/DMH012
Precocious puberty and statural growth.
Jean-Claude Carel (2004)
10.1210/JC.2006-1569
Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children.
E. M. Resende (2007)
10.1530/EJE.1.02056
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Jean-Claude Carel (2006)
10.1016/S0022-3476(05)81720-2
Local reactions to depot leuprolide therapy for central precocious puberty.
P. Manasco (1993)
10.1002/UOG.154
Pelvic ultrasound and color Doppler findings in different isosexual precocities.
C. Battaglia (2003)
10.1159/000084098
Very long-term follow-up of girls with early and late menarche.
Thérese Johansson (2005)
10.1210/JCEM.86.9.7852
Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
L. Lazar (2001)
10.1136/adc.2007.115709
Suppression of menstruation in adolescents with severe learning disabilities
A. Albanese (2007)
10.1016/j.mce.2006.04.012
Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function
S. Heger (2006)
10.1210/jc.2009-0793
The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
M. A. Magiakou (2010)
10.1542/PEDS.109.1.61
Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities.
M. Chalumeau (2002)
10.1210/jcem.80.2.7852518
Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years.
D. Paul (1995)
10.1210/JC.2001-020243
Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
Jean-Claude Carel (2002)
10.1210/JCEM.85.11.6951
Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy.
P. Feuillan (2000)
10.1186/1471-2431-8-27
Idiopathic central precocious puberty in girls: presentation factors
Géraldine Prété (2008)
10.1210/JCEM.86.10.7915
Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.
K. Klein (2001)
10.1067/S0022-3476(03)00328-7
Selecting girls with precocious puberty for brain imaging: validation of European evidence-based diagnosis rule.
M. Chalumeau (2003)
10.1210/jc.2010-1025
Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration.
L. Soriano-Guillén (2010)
10.1176/appi.ajp.2010.09081190
Outcomes of early pubertal timing in young women: a prospective population-based study.
William E. Copeland (2010)
10.1530/EJE.1.02151
Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche.
L. de Vries (2006)
10.1542/PEDS.2005-0012
Prevalence and Incidence of Precocious Pubertal Development in Denmark: An Epidemiologic Study Based on National Registries
G. Teilmann (2005)
10.1159/000053237
Serum Inhibin A and Inhibin B in Central Precocious Puberty before and during Treatment with GnRH Agonists
A. Sehested (2000)
10.1056/NEJMCP0800459
Precocious puberty.
Jean-Claude Carel (1986)
10.1210/jc.2013-1024
Treatment and outcomes of precocious puberty: an update.
J. Fuqua (2013)
10.1542/peds.2008-1783
Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
Jean-Claude Carel (2009)
10.1111/j.1745-7262.2008.00409.x
Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.
S. Bertelloni (2008)
10.1007/BF01954267
Pelvic ultrasonography: Early differentiation between isolated premature thelarche and central precocious puberty
H. P. Haber (2005)
10.1515/JPEM.2000.13.S1.687
Etiology of Central Precocious Puberty in Males: The Results of the Italian Study Group for Physiopathology of Puberty
V. De Sanctis (2000)
10.1016/j.fertnstert.2012.07.1118
Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
C. Hagen (2012)
10.1210/JCEM.84.10.6032
Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study.
C. Bouvattier (1999)
10.1210/JC.2007-0321
Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity.
L. Lazar (2007)
10.1016/S0022-3476(95)70255-5
Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty.
E. Neely (1995)
10.1210/JCEM.84.2.5430
Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients.
M. Palmert (1999)
10.1515/JPEM.2000.13.S1.723
Pharmacokinetics and Pharmacodynamics of GnRH Agonists: Clinical Implications in Pediatrics
N. Lahlou (2000)
10.1046/j.1365-2265.2001.01229.x
Central precocious puberty: clinical and laboratory features *
W. Chemaitilly (2001)
10.1056/NEJM198112243052602
Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report.
F. Comite (1981)
10.1210/JCEM.84.2.5533
Precocious puberty: who has it? Who should be treated?
K. Klein (1999)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar